China Ophthalmology Drugs Market (2025-2030)
The China Ophthalmology Drugs Market was valued at $512.5 Million in 2025 and projected to reach to $725.5 Million by 2030, representing a compound annual growth rate of 7.2%. China's ophthalmology drugs market is positioned for sustained growth through 2030, driven by demographic shifts, rising disposable incomes, and enhanced healthcare accessibility.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Ophthalmology Drugs Market Trends and Insights
- This growth trajectory reflects China's aging population, rising prevalence of eye disorders, and increasing healthcare investment in the region.
- China's market is outpacing the global average of 6.1% CAGR, driven by enhanced access to ophthalmic treatments and growing awareness of vision care among urban and rural populations. The ophthalmology drugs sector in China benefits from government healthcare reforms and pharmaceutical innovation initiatives.
- China's pharmaceutical industry is rapidly developing novel treatments for conditions such as dry eye disease, glaucoma, and age-related macular degeneration.
- Between 2025 and 2030, China is expected to see accelerated adoption of advanced ophthalmic therapies, supported by expanding healthcare infrastructure and rising disposable incomes. China's strategic position in the Asia Pacific region positions it as a key growth engine for ophthalmology drugs.
- Market players in China are capitalizing on regulatory improvements and increased R&D investments to capture growing demand.
- The forecast period through 2030 will be critical for establishing market presence in China's competitive and rapidly evolving ophthalmology landscape..
Key Market Statistics
- CAGR (2025-2030) 7.2% CAGR
- Market Size, 2025 ~USD 512.5 Million
- Forecast, 2030 ~USD 725.5 Million
- Country China
China Ophthalmology Drugs Market Overview
Aging Population Driving Demand :
China's rapidly aging demographic is significantly increasing the prevalence of age-related eye conditions such as cataracts, glaucoma, and age-related macular degeneration, creating sustained demand for ophthalmology drugs.
Government Healthcare Investment :
Increased government funding for healthcare infrastructure and pharmaceutical accessibility across urban and rural China is expanding patient reach and improving treatment adoption rates for ophthalmic conditions.
Rising Myopia Epidemic :
China faces a critical myopia crisis, particularly among children and young adults, driving demand for preventive and corrective pharmaceutical interventions and creating a large addressable market segment.
Outpacing Global Growth :
China's ophthalmology drugs market CAGR of 7.2% exceeds the global average of 6.1%, reflecting stronger market dynamics, regulatory improvements, and increasing healthcare spending in the region.
China Ophthalmology Drugs Market Dynamics
- The market's 7.2% CAGR reflects strong fundamentals including an aging population, high prevalence of myopia, and government initiatives to improve eye care services.
- Pharmaceutical companies are increasingly investing in China-specific formulations and distribution networks to capture this expanding opportunity. Looking ahead, market expansion will be supported by improved diagnostic capabilities, increased awareness campaigns, and integration of digital health solutions.
- Regulatory streamlining and faster drug approvals are expected to accelerate market entry for innovative therapies.
- As China continues to prioritize healthcare modernization and preventive medicine, the ophthalmology drugs sector will benefit from both volume growth and premiumization of treatment options..
Related Ecosystem
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- Merck KGaA
- SANOFI
- Pfizer Inc.
- NOVARTIS
Key Takeaways
- China's ophthalmology drugs market will grow from $512.5M (2025) to $725.5M (2030) at a 7.2% CAGR, outpacing global growth.
- China's aging demographic and rising eye disease prevalence are primary drivers of market expansion through 2030.
- Government healthcare reforms and pharmaceutical innovation in China are accelerating adoption of advanced ophthalmic treatments.
- China represents a strategic growth opportunity in Asia Pacific, with expanding healthcare infrastructure supporting market penetration.
Ophthalmology Drugs Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | FARICIMAB (Molecule) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6.1% from 2025 to 2030 |
| Largest Segment | INTRAVITREAL (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 19.55 (2025) |
| Revenue Forecast (Billions) | ~USD 26.28 (2030) |
| Segments Covered | Molecule, Modality, Indication, Type, Route Of Administration, End User |
China Ophthalmology Drugs Market Report Segmentation
6 segment dimensions are covered across the global market.
By Molecule
- Aflibercept
- Faricimab
- Other Molecules
- Ranibizumab
By Modality
- Monoclonal Antibodies & Fusion Proteins
- Other Modalities
- Small Molecules
By Indication
- Age-Related Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Other Indications
By Type
- Dry Amd
- Wet Amd
By Route Of Administration
- Intravitreal
- Other Routes Of Administration
- Topical
By End User
- Hospitals
- Long-Term Care Facilities
- Specialty Centers
CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 607.5 | 556.8 | 592 | 629.3 | 670.1 | 713.4 | 758.6 | 807.5 | 6.4 |
| LONG-TERM CARE FACILITIES | 129.1 | 112.3 | 118.9 | 125.9 | 133.6 | 141.7 | 150 | 159.1 | 6 |
| SPECIALTY CENTERS | 55.8 | 54.4 | 57.3 | 60.3 | 63.6 | 67.1 | 70.7 | 74.5 | 5.4 |
| TOTAL | 792.5 | 723.4 | 768.3 | 815.6 | 867.3 | 922.1 | 979.3 | 1041 | 6.3 |
Target Audience
- Pharmaceutical Manufacturers : Need market-specific data to guide R&D investments, product launches, and commercial strategies in China's high-growth ophthalmology segment, including competitive positioning and regulatory pathways.
- Healthcare Investors & PE Firms : Require validated market sizing and growth forecasts to evaluate investment opportunities in Chinese ophthalmology companies, drug developers, and healthcare service providers.
- Medical Device & Diagnostic Companies : Seek understanding of China's ophthalmology market dynamics to identify complementary product opportunities, partnership potential, and market expansion strategies aligned with pharmaceutical growth.
- Healthcare Consultants & Advisors : Need authoritative China-specific market data to support client strategy development, competitive analysis, and market entry planning for ophthalmology sector stakeholders.
- Government & Policy Organizations : Require market intelligence on China's ophthalmology drug landscape to inform healthcare policy, reimbursement strategies, and public health initiatives addressing vision care accessibility.
Key Companies in the China Ophthalmology Drugs Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| REGENERON PHARMACEUTICALS INC. | United States | Public Company | Ophthalmology (EYLEA franchise),Immunology / Inflammation (Dupixent, Kevzara),Oncology / Hematology (Libtayo, bispecifics pipeline), |
| BAYER AG | Germany | Public Company | Crop Science (seeds, traits, crop protection, digital ag, services),Pharmaceuticals (cardiology, women’s health, oncology, hematology, ophthalmology, imaging, cell & gene),Consumer Health (OTC, self-care, supplements, dermatology, pain, digestive), |
| NOVARTIS AG | Switzerland | Public Company | Oncology and Hematology (Kisqali, Tafinlar+Mekinist, Pluvicto, Lutathera, Scemblix, Promacta/Revolade, Jakavi, Fabhalta),Cardiovascular, Renal and Metabolic (Entresto, Leqvio and related CVRM portfolio),Immunology and Neuroscience (Cosentyx, Xolair, Ilaris and related assets), |
| ABBVIE | United States | Public Company | Immunology (Skyrizi, Rinvoq and related),Oncology/Hematology (Imbruvica, Venclexta, Epkinly, Elahere, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev, migraine portfolio), |
| APELLIS PHARMACEUTICALS | United States | Private Company | SYFOVRE – Geographic Atrophy,EMPAVELI – PNH and related indications,Pipeline and collaborations (APL-3007, APL-9099, Beam partnership), |
| BIOGEN | United States | Public Company | Multiple sclerosis franchise (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SMA and rare neurology (SPINRAZA, SKYCLARYS, QALSODY, zorevunersen pipeline linkage),Alzheimer’s and psychiatry (LEQEMBI, ZURZUVAE), |
| BAUSCH + LOMB | Canada | Public Company | Vision Care (contact lenses, lens care, OTC eye care, vitamins),Pharmaceuticals (Rx and generic ophthalmics),Surgical (cataract, corneal, vitreous, retinal devices and IOLs), |
| ASTELLAS PHARMA INC. | Japan | Public Company | Oncology (XTANDI, XOSPATA, VYLOY, PADCEV),Urology (Betanis/Myrabetriq/BETMIGA),Immunology / Transplant (Prograf), |
| FORMYCON AG | Germany | Public Company | Ranibizumab biosimilars (ophthalmology),Aflibercept biosimilars (ophthalmology),Ustekinumab biosimilar pipeline/early revenues, |
| BIOCON | India | Public Company | Biosimilars (oncology, diabetes, immunology),Generics and APIs,CRDMO (discovery, development, manufacturing services), |
| SANDOZ GROUP AG | Switzerland | Public Company | Small-molecule generics (oral and injectable),Biosimilars,Specialty and rare disease off-patent medicines, |
| SANTEN PHARMACEUTICAL CO., LTD. | Japan | Public Company | Glaucoma & ocular hypertension therapies,Dry eye & keratoconjunctival disease,Allergic conjunctivitis & inflammatory eye disease, |
| INNOVENT | China | Public Company | Oncology immunotherapy (PD-1, CTLA-4, combinations),Oncology targeted therapies and cell therapy,Autoimmune and ophthalmology biologics, |
| OUTLOOK THERAPEUTICS, INC. | United States | Public Company | ONS-5010 (ophthalmic bevacizumab for wet AMD and retinal diseases),Other pipeline / platform and collaboration-derived income, |
REGENERON PHARMACEUTICALS INC.
Regeneron Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1988 with 15,343 employees. The company focuses on the discovery, development, and commercialization of medicines.
BAYER AG
Bayer AG is a German public company founded in 1863 with 87,757 employees, operating across pharmaceuticals, consumer health, and agricultural sciences. The company is one of the world's largest diversified life sciences organizations.
NOVARTIS AG
Novartis AG is a Swiss public pharmaceutical company founded in 1996 with 75,267 employees. The company develops and manufactures a broad range of innovative medicines and healthcare products.
ABBVIE
AbbVie is a United States-based public pharmaceutical company founded in 2012 with 57,000 employees. The company discovers, develops, and markets pharmaceutical products across multiple therapeutic areas.
APELLIS PHARMACEUTICALS
Apellis Pharmaceuticals is a United States-based private biopharmaceutical company founded in 2009 with 736 employees. The company focuses on the development of novel therapeutic candidates.
BIOGEN
Biogen is a United States-based public biotechnology company founded in 1978 with 7,500 employees. The company discovers, develops, manufactures, and delivers medicines primarily in neurology and immunology.
BAUSCH + LOMB
Bausch + Lomb is a Canadian public company founded in 1853 with 13,000 employees specializing in eye health and vision care products. The company is a global leader in the eye care industry.
ASTELLAS PHARMA INC.
Astellas Pharma Inc. is a Japanese public pharmaceutical company founded in 1923 with 14,099 employees. The company researches, develops, and commercializes pharmaceutical products worldwide.
FORMYCON AG
Formycon AG is a German public biopharmaceutical company founded in 1999 with 203 employees. The company specializes in the development of biosimilar medicines.
BIOCON
Biocon is an Indian public biopharmaceutical company founded in 1978 with 16,447 employees. The company develops and manufactures biopharmaceuticals, including biosimilars and small molecule drugs.
SANDOZ GROUP AG
Sandoz Group AG is a Swiss public pharmaceutical company founded in 1886 with 22,356 employees. The company is a global leader in generic and biosimilar medicines.
SANTEN PHARMACEUTICAL CO., LTD.
Santen Pharmaceutical Co., Ltd. is a Japanese public pharmaceutical company founded in 1890 with 3,968 employees. The company specializes in ophthalmic and other pharmaceutical products.
INNOVENT
Innovent is a Chinese public biopharmaceutical company founded in 2011 with 7,502 employees. The company focuses on the research and development of innovative biologics.
OUTLOOK THERAPEUTICS, INC.
Outlook Therapeutics, Inc. is a United States-based public biopharmaceutical company founded in 2010 with 17 employees. The company develops and commercializes ophthalmic therapeutic products.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation ($512.5M in 2025) and verified growth projections through 2030, enabling accurate financial forecasting and investment decision-making specific to China's ophthalmology sector.
- Competitive Positioning Intelligence : Understand China's market dynamics relative to global trends (7.2% vs 6.1% CAGR), identifying competitive advantages and market gaps to inform product development and market entry strategies.
- Demographic & Disease Insights : Access detailed analysis of China's aging population, myopia epidemic, and prevalence of eye disorders, enabling targeted marketing strategies and product positioning for specific patient segments.
- Regulatory & Access Landscape : Gain insights into China's healthcare investment trends, drug approval pathways, and distribution infrastructure to optimize market entry timelines and commercial strategies.
- Strategic Investment Guidance : Leverage comprehensive market data to identify high-growth therapeutic areas, geographic opportunities, and partnership potential within China's rapidly expanding ophthalmology drugs market.
Frequently asked questions
What is the current size of China's ophthalmology drugs market?
China's ophthalmology drugs market is valued at $512.5 million in 2025 and is projected to grow to $725.5 million by 2030.
What is the CAGR for China's ophthalmology drugs market?
China's ophthalmology drugs market is expected to grow at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2030.
What are the main drivers of growth in China's ophthalmology drugs market?
Key growth drivers in China include an aging population, rising prevalence of eye disorders, government healthcare reforms, pharmaceutical innovation, and increasing healthcare investment and awareness.
How does China's ophthalmology drugs market compare to global growth?
China's market is growing at 7.2% CAGR, which exceeds the global average of 6.1%, positioning China as a faster-growing market within the ophthalmology drugs sector.
What ophthalmic conditions are driving demand in China?
Major conditions driving demand in China include dry eye disease, glaucoma, and age-related macular degeneration, with increasing treatment adoption expected through 2030.
RESEARCH METHODOLOGY
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global ophthalmology drugs market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the ophthalmology drugs market. The secondary sources used for this study include US Food and Drug Administration (US FDA), European Medicines Agency (EMA), World Health Organization (WHO), National Center for Biotechnology Information (NCBI), White papers, Company Websites, Interviews with Experts, Annual Reports, SEC Filings, Investor Presentations, and MarketsandMarkets Analysis. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
A comprehensive primary research was undertaken following an initial assessment of the global ophthalmology drugs market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from hospitals, long-term care facilities, and specialty centers. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the ophthalmology drugs market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the ophthalmology drugs market was generated.
- The revenues generated from their ophthalmology drug products have been determined through annual reports and secondary sources (including paid databases).
- The products were mapped according to the segments of the market. Percentage shares and splits were determined based on the revenue contributed to each segment. This was verified using secondary sources and by industry experts.
- All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.
Global Ophthalmology Drugs Market Size: Bottom-up and Top-down Approaches
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Ophthalmology drugs are specifically designed to treat or prevent eye diseases and disorders. These medications target various parts of the eye, including the cornea, conjunctiva, lens, retina, and optic nerve. The market includes a range of effective therapies across different drug modalities, such as biologics and biosimilars (e.g., anti-VEGF drugs, monoclonal antibodies, oligonucleotides, and peptides), small molecules, gene therapy, and cell therapy. These treatments address various conditions, including age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, retinal vein occlusion, uveitis, and neurotrophic keratitis, among others.
Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals
- Patient advocacy organizations
- Specialty clinics
- Long-term care facilities
- Academic researchers and government research organizations
- Private research institutes
- Contract manufacturing organizations (CMOs)
- Contract research organizations (CROs)
- Venture capitalists
Report Objectives
- To define, describe, and forecast the ophthalmology drugs market by molecule, modality, route of administration, indication, end user, and region
- To provide detailed information regarding the factors influencing market growth (such as drivers, opportunities, restraints, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall ophthalmology drugs market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To profile the key players in the global ophthalmology drugs market as well as comprehensively analyze their core competencies and market rankings
- To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To track and analyze competitive developments, such as product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements, in the ophthalmology drugs market
Get the Full Ophthalmology Drugs Market Report
Full forecast, segment splits, and company analysis for all Ophthalmology Drugs Market.
- US Ophthalmology Drugs Market
- Canada Ophthalmology Drugs Market
- Germany Ophthalmology Drugs Market
- UK Ophthalmology Drugs Market
- France Ophthalmology Drugs Market
- Italy Ophthalmology Drugs Market
- Spain Ophthalmology Drugs Market
- Japan Ophthalmology Drugs Market
- India Ophthalmology Drugs Market
- Australia Ophthalmology Drugs Market
- South Korea Ophthalmology Drugs Market
- Brazil Ophthalmology Drugs Market
- Mexico Ophthalmology Drugs Market
- Rest Of Europe Ophthalmology Drugs Market
- Rest Of Asia Pacific Ophthalmology Drugs Market
- Rest Of Latin America Ophthalmology Drugs Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
